Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes inadequately controlled or intolerant to metformin~* Obtaining informed consent~* Aged between 18 and 70 years~* BMI between 20 and 45 kg / m²~Exclusion Criteria:~* Contraindication to nuclear magnetic resonance (NMR):~* Carrying a metallic foreign body (pacemaker, valve, intraocular equipment, clips)~* Allergy to Gadolinium / Secretin~* Pregnancy or breastfeeding~* Contraindication to treatment with incretinomimetic:~* Hypersensitivity to the active substance or to any of the excipients~* Severe Gastroparesis~* Severe renal impairment~* History of Surgery (gastroduodenal, pancreatic or ileocecal)~* Presence or history of pancreatic disease~* Active alcoholism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sulfonylurea (Type: ACTIVE_COMPARATOR): Patient will received metformine with sulfonylurea
- Incretinomimectics (Type: ACTIVE_COMPARATOR): Patients will received metformin with sulfonylurea with GLP-1 analogue
- DPP-4 inhibitors (Type: ACTIVE_COMPARATOR): Patients will received metformin with DPP-4 inhibitors

Based on this trial design, predict the completion outcome and termination type (if applicable).